Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes.

@article{Spinner2010ImpactOP,
  title={Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes.},
  author={Michael L Spinner and Georges Saab and Ed Casabar and Lyndsey J Bowman and Gregory A Storch and Daniel C. Brennan},
  journal={Transplantation},
  year={2010},
  volume={90 4},
  pages={412-8}
}
BACKGROUND Both prophylactic and preemptive oral valganciclovir therapy are effective for the management of cytomegalovirus (CMV) postrenal transplantation in the short term. The long-term effect of either strategy is less well defined. METHODS We analyzed the data on 115 adult recipients previously enrolled in a prospective randomized controlled trial of prophylaxis versus preemptive therapy for CMV. The primary outcome was a composite of freedom from acute rejection, graft loss, or death… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.

Transplant international : official journal of the European Society for Organ Transplantation • 2013
View 3 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2008
View 3 Excerpts

Management of cardiovascular disease in renal transplant recipients.

Clinical journal of the American Society of Nephrology : CJASN • 2008
View 1 Excerpt

Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2008

Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2007
View 2 Excerpts

Similar Papers

Loading similar papers…